Skip to content
Medicare’s 2026 Open Enrollment period for Part D plans began on Oct. 15 and runs through Dec. 7. “As patient advocates have seen year […]
BIO Coffee Chat: Guiding patients through Part D open enrollment Read More »
At a time when the biopharma industry is seeking to increase U.S. manufacturing, Indiana is in the vanguard—and still expanding. During a Nov. 11
BIO on the American Road: Indiana, a production powerhouse, is still expanding Read More »
Venture capital funding for life sciences startups plummeted after legal changes weakened the patent system, according to new research that confirms the close relationship
Ahead of BIO IP Conference, research highlights why biotech needs strong patents Read More »
Three years after the passage of the Inflation Reduction Act (IRA), patient advocates and the biotech industry are working to navigate downstream negative impacts
PACE: Downstream effects of IRA on patients Read More »
Luke Rosen had hoped a new treatment would slow the progression of his daughter’s KIF1A Associated Neurological Disorder (KAND), but was amazed to see
PACE panel urges incentives for exciting new GTT drugs Read More »
The 340B program, in recent decades, has shown how the best laid plans can go sideways when not kept transparent and properly in check.
PACE: How 340B outgrew its goal and stopped helping patients Read More »
Maintaining America’s biotechnology leadership requires Food and Drug Administration (FDA) modernization as well as Congressional action to reauthorize a program supporting rare disease research
BIO CEO John Crowley tells Senate how to support biotech Read More »
October is Breast Cancer Awareness Month, and to mark the occasion, Bio.News has partnered with the Tigerlily Foundation to explore how they developed their
A legacy of love, leadership, and liberation: Tigerlily’s next chapter Read More »
With Medicaid cuts expected, vaccine hesitancy getting politicized, and the continued challenge of Prescription Drug Affordability Boards (PDABs), state legislatures will drive many of
BIO PACE 2025: Patients need to ensure state policies enable access to medicine Read More »
The post-COVID era has not been kind to legislation supportive of vaccines, on either the state or the federal level. But advocates have persisted
BIO PACE 2025: Why patient advocates are key to the vaccine conversation Read More »
